NL-OMON46408已完成不适用
An open-label, single-sequence study to investigate the effects of BMS-986165 on the single-dose pharmacokinetics of methotrexate in healty male subjects. - BMS-986165 open-label, DDI study
Bristol-Myers Squibb Research and Development0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- healthy male subjects
- •- 18-50 yrs, inclusive
- •- BMI: 18.0-32.0 kg/m2, inclusive
- •- non-smoking
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
An open-label, single-sequence study to investigate the effects of gastric acid suppression by Rabeprazole on the pharmacokinetics of BMS-986165 in healthy participantsPsoriasissystemic lupus erythematosus and Crohn's disease.10003816NL-OMON47975BritsolMyers Squibb Research and Development20
已完成
不适用
An Open-label, Single-Sequence Study to Evaluate the Effects of Diltiazem, a Moderate CYP3A4/5 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of E5555 and its Metabolites in Healthy Subjectscardiovascular eventsthrombosis10003216NL-OMON34620Eisai24
已完成
1 期
To determine whether a pharmacokinetic drug-drug interaction occurs between atorvastatin and elinogrel.chronic coronary heart disease (CHD)Cardiovascular - Coronary heart diseaseACTRN12611000315910ovartis Pharmaceutical Pty Limited28
招募中
不适用
A Study to Evaluate the Effect of Gumiganghwaltang on the Pharmacokinetics of Caffeine after Oral Administration of Caffeine in Healthy Male VolunteersDiseases of th respiratory systemKCT0001812Kyung Hee University Oriental Medical Center8
已完成
不适用
An open label, single center study to investigate the metabolic profile of dalcetrapib after a single oral dose in healthy male subjectscoronary heart disease10011082NL-OMON35295F. Hoffmann-La Roche Ltd.6